Keenova Therapeutics has announced encouraging results from its Phase 3 trial of XIAFLEX®, targeting plantar fibromatosis, a condition with limited treatment options.

Keenova Therapeutics has unveiled clinical data on a nonsurgical treatment for plantar fibromatosis. The findings, revealed at the ACFAS meeting, show promising safety and effectiveness.

Endo shares groundbreaking findings on plantar fibromatosis and fasciitis at the AOFAS Annual Meeting, emphasizing advances in treatment options.

Endo, Inc. shares groundbreaking research at the American Podiatric Medical Association Annual Meeting, showcasing advancements in treatments for plantar fibromatosis and fasciitis.